Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia
This study has been completed.
Study NCT00261573 Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
First Received on December 2, 2005. Last Updated on May 17, 2011
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Alzheimer Disease
Vascular Dementia
Additional conditions recognized in this trial
Dementia
Dementia, Vascular
More general conditions related to this trial
Arterial Occlusive Diseases
Arteriosclerosis
Brain Diseases
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Delirium, Dementia, Amnestic, Cognitive Disorders
Intracranial Arterial Diseases
Intracranial Arteriosclerosis
Leukoencephalopathies
Mental Disorders
Nervous System Diseases
Neurodegenerative Diseases
Tauopathies
Vascular Diseases
Interventions listed in this trial
galantamine hydrobromide
Additional drug interventions recognized in this trial
Galantamine
More general drug interventions related to this trial
Autonomic Agents
Central Nervous System Agents
Cholinergic Agents
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Nootropic Agents
Parasympathomimetics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Back to top of Main Content
